Review Article
Volume 12 Issue 2 - 2021
Ocular Problems after Hematopoietic Stem Cell Transplantation
Dorota Kopacz*, Piotr Maciejewicz and Amelia H Kopacz
Department of Ophthalmology, Medical University of Warsaw, Warsaw, Poland
*Corresponding Author: Dorota Kopacz, Department of Ophthalmology, Medical University of Warsaw, Warsaw, Poland.
Received: October 10, 2020; Published: January 27, 2021




Abstract

Hematopoietic stem cell transplantation (HSCT) is a common treatment for many hematologic malignant and non-malignant disorders. Graft-versus-host disease (GVHD) is one of the major, unrelated with rejection, complications after HCT. Ocular involvement occurs in more than fifty percent of patients with GVHD after HSCT and ranges from mild conjunctivitis to severe cicatricial conjunctivitis and corneal perforation. Non-GVHD ocular complications after HSCT are uncommon and include: cataract, glaucoma, ocular infections, ocular involvement of malignancy, ischemic microvascular retinopathy, central vein occlusion, retinal hemorrhage, retinal detachment, ocular toxicities of medications. Both GVHD and non-GVHD ocular complications can cause prolongated morbidity affecting patients’ quality of life and function. We would like to present recent updates in ocular disorders after HSCT, to highlight the relevance of ophthalmological examination before and after HSCT and to stress the importance of collaboration between transplant physicians and ophthalmologists for optimal recipients care.

Keywords: Graft-Versus-Host Disease; Eye Complications; Dry Eye; Hematopoietic Cell Transplantation

References

  1. Nassiri N., et al. “Ocular Graft Versus Host Disease Following Allogenic Stem Cell Transplantation: A Review of Current Knowledge and Recommendations”. Journal of Ophthalmic and Vision Research 4 (2013): 351-358.
  2. Na KS., et al. “Incidence and risk factors for ocular GVHD after allogenic hematopoietic stem cell transplantation”. Bone Marrow Transplantation 50 (2015): 1459-1464.
  3. Shikari H., et al. “Onset of Ocular Graft-Versus-Host Disease Symptoms After Allogenic Hematopoietic Stem Cell Transplantation”. Cornea3 (2015): 243-247.
  4. Kopacz D and Maciejewicz P. “Objawy okulistyczne w przebiegu choroby „przeszczep przeciwko gospodarzowi” po allogenicznym przeszczepie komórek macierzystych szpiku/Ocular Manifestation of Graft-Versus-Host Disease Following Allogenic Hematopoietic Stem Cells Transplantation, Okulistyka (2016): 35-37.
  5. Ferrara JLM., et al. “Graft-Versus-Host Disease”. Lancet 9674 (2009): 1550-1561.
  6. Stokłosa T and Gaciong Z. “Immunologia transplantacyjna”. Immunologia pod red. Gołąb J, Jakóbisiak M, Lasek W, Stokłosa T, Wydawnictwo Naukowe PWN (2007): 444-468.
  7. Berchicci L., et al. “Ocular chronic graft-versus-hst disease after allogenic hematopoietic stem cell transplantation in an Italian referral center”. The Ocular Surface 16 (2018): 314-321.
  8. Inamoto Y., et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation”. Biology of Blood and Marrow Transplantation 2 (2019): e46-e54.
  9. Inamoto Y., et al. “Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation”. Biol Blood Marrow Transplant5 (2019): e145-e154.
  10. Curtis LM., et al. “Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice”. Haematologica,9 (2015): 1228-1236.
  11. Qiu Y., et al. “Manifestation of Clinical Categories of Ocular Graft-versus-Host Disease”. American Journal of Ophthalmology (2018): 6430953.
  12. Pathak M., et al. “Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation”. Bone Marrow Transplant 7 (2018): 863-872.
  13. Filipovich AH., et al. “National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic Graft-versus-Host Disease: I. Diagnosis and Stagineg Working Group Report”. Biology of Blood and Marrow Transplantation 11 (2005): 945-956.
  14. Martin P., et al. “Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation”. Bone Marrow Transplant 3 (1998): 273-279.
  15. Fahnehjelm KT., et al. “Dry-eye syndrome after allogenic stem-cell transplantation in children”. Acta Ophthalmologica 86 (2008): 253-258.
  16. Lin X and Cavanagh HD. “Ocular manifestation of graft-versus-host disease:10 years’ experience”. Clinical Ophthalmology 9 (2015): 1209-1213.
  17. Dietrich-Ntoukas T., et al. “Diagnosis and treatment of ocular Graft-versus-Host Disease: Report from German-Austrian-Swiss Consensus Conference on clinical practice in chronic GVHD”. Cornea 31 (2012): 299-310.
  18. Nassar A., et al. “Ocular manifestation of graft-versus-host disease”. Saudi Journal of Ophthalmology 27 (2013): 215-222.
  19. Hessen M and Akpek EK. “Ocular graft-versus-host disease”. Current Opinion in Allergy and Clinical Immunology 12 (2012): 540-547.
  20. Anderson NG and Regillo C. “Ocular manifestation of graft versus host disease”. Current Opinion in Ophthalmology 15 (2004): 503-507.
  21. Saboo US., et al. “Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-hoste disease”. Graefe's Archive for Clinical and Experimental Ophthalmology 5 (2016): 923-928.
  22. Ghimire S., et al. “Pathophysiology of GvHD and Other HSCT-Related Major Complications”. Frontiers in Immunology 8 (2017): 79.
  23. Kernan NA., et al. “Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease”. Blood 3 (1986): 770-773.
  24. Martin PJ., et al. “A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment”. Blood 76 (1990): 1464-1472.
  25. Sullivan KM., et al. “Chronic graft-versus-host disease and other late complications of bone marrow transplantation”. Semin Hemat 28 (1991): 250-259.
  26. Sullivan KM., et al. “Late complications of allogeneic and autologous marrow transplantation”. Bone Marrow Transplant 10 (1992): 127-134.
  27. Vogelsang GB., et al. “Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant”. Annual Review of Medicine 54 (2003): 29-52.
  28. Cooke KR., et al. “An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin”. Blood 88 (1996): 3230-3239.
  29. Jagasia MH., et al. “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report”. Biol Blood Marrow Transplant3 (2015): 389-401.
  30. Min Chang-KI. “The pathophysiology of chronic graft-versus-host disease: the unvelling of an enigma”. The Korean Journal of Hematology 2 (2011): 80-87.
  31. Socié G and Ritz J. “Current issues in chronic graft-versus-host disease”. Blood3 (2014): 374-384.
  32. Sarantopoulos S and Ritz J. “Aberrant B-cell homeostasis in chronic GVHD”. Blood11 (2015): 1703-1707.
  33. Kim S. “Ocular Graft-versus-Host Disease”. In Cornea. Fundamentals, diagnosis and management. 3-rd edition by Krachmer JH, Mannis MJ, Holland EJ. Mosby (2011).
  34. Jabs DA., et al. “The eye in bone marrow transplantation. III. Conjunctival graft vshost disease”. Archives of Ophthalmology 107 (1989): 1343-1348.
  35. Hirst LW., et al. “The Eye in Bone Marrow Transplantation: I”. Clinical Study Archives of Ophthalmology 4 (1983): 580-584.
  36. Jack MK., et al. “Ocular Manifestations of Graft-v-Host Disease”. Archives of Ophthalmology 7 (1983): 1080-1084.
  37. Espana EM., et al. “Graft versus host disease: clinical evaluation, diagnosis and management”. Graefe's Archive for Clinical and Experimental Ophthalmology 251 (2013): 1257-1266.
  38. Strouthidis NG., et al. “Posterior segment complications of graft versus host disease after bone marrow transplantation”. British Journal of Ophthalmology 11 (2003): 1421-1423.
  39. Kim SK. “Update on ocular graft versus host disease”. Current Opinion in Ophthalmology 17 (2006): 344-348.
  40. Robinson MR., et al. “Topical corticosteroid therapy for cicatrical conjunctivitis associated with chronic graft-versus-host disease”. Bone Marrow Transplant 33 (2004): 1031-1035.
  41. Kim SK., et al. “Ocular graft vs. host disease experience from MD Anderson Cancer Center: Newly described clinical spectrum and new approach to the management of stage III and IV ocular GVHD”. Biology of blood and Marrow Transplantation2 (2006): 49-50.
  42. Inamoto Y., et al. “Chronic GVHD Consortium. Validation of measurement scales in ocular graft-versus-host disease”. Ophthalmology3 (2012): 487-493.
  43. Ogawa Y., et al. “International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I)”. Scientific Reports 3 (2013): 3419.
  44. Coskuncan NM., et al. “The Eye in Bone Marrow Transplantation: VI. Retinal Complications”. Archives of Ophthalmology 3 (1994): 372-379.
  45. Kim RY., et al. “Scleritis as the initial clinical manifestation of graft-versus-host disease after allogenic bone marrow transplantation”. American Journal of Ophthalmology 6 (2002): 843-845.
  46. Cheng LL., et al. “Graft-vs-host-disease-associated conjunctival chemosis and central serous chorioretinopathy after bone marrow transplant”. American Journal of Ophthalmology 2 (2002): 293-295.
  47. Adrean SD and Puklin JE. “Perforated corneal ulcer with subsequent endophthalmitis in a patient with graft-versus-host disease”. Cornea1 (2007): 107-108.
  48. Tichelli A., et al. “Cataract formation after bone marrow transplantation”. Annals of Internal Medicine 12 (1993): 1175-1180.
  49. Benyunes MC., et al. “Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation”. International Journal of Radiation Oncology • Biology • Physics 3 (1995): 661-670.
  50. Tomblyn M., et al. “Center for International Blood and Marrow Research, National Marrow Donor program, European Blood and Marrow Transplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Disease Canada, and Centers for Disease Control and Prevention (2009). Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective”. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation10 (2009): 1143-1238.
  51. Tabbara KF., et al. “Ocular findings after allogeneic hematopoietic stem cell transplantation”. Ophthalmology9 (2009): 1624-1629.
  52. Sumi M., et al. “Acute exacerbation of Toxoplasma gondii infection after hematopoietic stem cell transplantation: five case reports among 279 recipients”. International Journal of Hematology 2 (2013): 214-222.
  53. Crippa F., et al. “Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation”. Clinical Infectious Diseases 2 (2001): 214-219.
  54. Chen Y., et al. “Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation”. Clinical Infectious Diseases 4 (2000): 927-935.
  55. Koc Y., et al. “Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome”. Biology of Blood and Marrow Transplantation 1 (2000): 44-49.
  56. Castleton A and Kottaridis PD. “A case of 'red eye' post allogeneic stem cell transplantation”. Bone Marrow Transplant4 (2007): 241-242.
  57. Matsuo T., et al. “Intraocular Relapse with Hypopyon and Retinal Infiltrates after Chemotherapy and Peripheral Blood Stem Cell Transplantation for Extranodal NK/T-Cell Lymphoma”. Journal of Clinical and Experimental Hematopathology 3 (2015): 157-161.
  58. Green W., et al. “Extramedullary Relapse of Acute Myelogenous Leukemia Presenting as a Large Serous Retinal Detachment”. Ocular Oncology and Pathology 2 (2017): 95-100.
  59. Takeda A., et al. “Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity”. International Journal of Radiation Oncology • Biology • Physics 3 (1999): 599-605.
  60. Tripathi RC., et al. “Corticosteroids and glaucoma risk”. Drugs Aging6 (1999): 439-450.
  61. Bernauer W., et al. “Microvasculopathy in the ocular fundus after bone marrow transplantation”. Annals of Internal Medicine 12 (1991): 925-930.
  62. Kanski’s Clinical Ophthalmology. A systemic approach. 8th edition by Bowling B. Elsevier Limited 2016”. Polish edition by Edra Urban and Partner (2017): 572.
  63. O'Riordan JM., et al. “Retinal microvascular changes following bone marrow transplantation: the role of cyclosporine”. Bone Marrow Transplant1 (1994): 101-104.
  64. Gloor B., et al. “Multiple cotton wool spots following bone marrow transplantation for treatment of acute lymphatic leukaemia”. British Journal of Ophthalmology 5 (1985): 320-325.
  65. Bylsma GW., et al. “Atypical retinal microvasculopathy after bone marrow transplantation”. Clinical and Experimental Ophthalmology 4 (2001): 225-259.
  66. Johnson DW., et al. “Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support”. Bone Marrow Transplant7 (1999): 785-792.
  67. Yoo YS., et al. “Posterior eye segment complications related to allogeneichematopoietic stem cell transplantation”. Retina1 (2017): 135-143.
  68. McGhee CN., et al. “Locally administered ocular corticosteroids: benefits and risks”. Drug Safety 1 (2002): 33-55.
  69. Abud TB., et al. “A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease”. Ophthalmology7 (2016): 1449-1457.
  70. Boucher HW., et al. “Newer systemic antifungal agents : pharmacokinetics, safety and efficacy”. Drugs18 (2004): 1997-2020.
  71. Jaanus SD. “Ocular side effects of selected systemic drugs”. Clinical and Experimental Optometry 4 (1992): 73-96.
  72. Richa S and Yazbek JC. “Ocular adverse effects of common psychotropic agents: a review”. CNS Drugs6 (2010): 501-526.
  73. Li J., et al. “Drug-induced ocular disorders”. Drug Safety 2 (2008): 127-141.
  74. Kopacz D., et al. “Tear Film - physiology and disturbances in various diseases and disorders. In Ocular Surface Diseases: Some Current Date on Tear Film Problem and Keratoconic Diagnosis by Kopacz D”. Intech Open (2020).
  75. Slattery A., et al. “Common ocular effects reported to a poison control center after systemic absorption of drugs in therapeutic and toxic doses”. Current Opinion in Ophthalmology 6 (2014): 519-523.
  76. Laties AM and Fraunfelder FT. “Ocular safety of Viagra, (sildenafil citrate)”. Transactions of the American Ophthalmological Society 97 (1999): 115-125.
  77. Maciejewicz P and Kopacz D. “Substancje pomocnicze zawarte w kroplach do oczu/The Pharmaceutical Excipients Commonly Used in Eye Drops”. Okulistyka 1 (2016): 33-36.
  78. Walsh K and Jones L. “The use of preservatives in dry eye drops”. Clinical Ophthalmology 13 (2019): 1409-1425.
  79. Askeroglu U., et al. “Pharmaceutical and herbal products that may contribute to dry eyes”. Plastic and Reconstructive Surgery 1 (2013): 159-167.
  80. Flowers ME., et al. “Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria”. Blood 11 (2011): 3214-3219.
Citation: Dorota Kopacz., et al. “Ocular Problems after Hematopoietic Stem Cell Transplantation”. EC Ophthalmology 12.2 (2021): 15-26.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk